

Ayca Gucalp

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4119581/publications.pdf>

Version: 2024-02-01

28
papers

3,333
citations

361413

20
h-index

526287

27
g-index

28
all docs

28
docs citations

28
times ranked

5316
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase II Trial of Bicalutamide in Patients with Androgen Receptor-Positive, Estrogen Receptor-Negative Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 5505-5512.	7.0	592
2	Obesity and Cancer Mechanisms: Tumor Microenvironment and Inflammation. <i>Journal of Clinical Oncology</i> , 2016, 34, 4270-4276.	1.6	578
3	American Society of Clinical Oncology Position Statement on Obesity and Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 3568-3574.	1.6	418
4	Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 884-890.	1.6	365
5	Male breast cancer: a disease distinct from female breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 37-48.	2.5	205
6	Systemic Correlates of White Adipose Tissue Inflammation in Early-Stage Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 2283-2289.	7.0	154
7	Phase II Trial of Saracatinib (AZD0530), an Oral SRC-inhibitor for the Treatment of Patients with Hormone Receptor-negative Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2011, 11, 306-311.	2.4	118
8	Triple-Negative Breast Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2010, 16, 62-65.	2.0	117
9	A phase 2 clinical trial assessing the efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer. <i>Cancer</i> , 2020, 126, 850-860.	4.1	116
10	Metabolic Obesity, Adipose Inflammation and Elevated Breast Aromatase in Women with Normal Body Mass Index. <i>Cancer Prevention Research</i> , 2017, 10, 235-243.	1.5	114
11	Menopause Is a Determinant of Breast Adipose Inflammation. <i>Cancer Prevention Research</i> , 2015, 8, 349-358.	1.5	90
12	Menopause Is a Determinant of Breast Aromatase Expression and Its Associations With BMI, Inflammation, and Systemic Markers. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 1692-1701.	3.6	77
13	Targeting the androgen receptor in triple-negative breast cancer. <i>Current Problems in Cancer</i> , 2016, 40, 141-150.	2.0	70
14	Triple-Negative Breast Cancer: Adjuvant Therapeutic Options. <i>Chemotherapy Research and Practice</i> , 2011, 2011, 1-13.	1.6	50
15	A Phase I/II Study of Enzalutamide Alone and in Combination with Endocrine Therapies in Women with Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 4046-4054.	7.0	43
16	Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 111-120.	2.5	38
17	A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 6149-6157.	7.0	29
18	âœ“A Tool, Not a Crutchâœ“ Patient Perspectives About IBM Watson for Oncology Trained by Memorial Sloan Kettering. <i>Journal of Oncology Practice</i> , 2019, 15, e277-e288.	2.5	28

#	ARTICLE	IF	CITATIONS
19	Targeting obesity-related adipose tissue dysfunction to prevent cancer development and progression. <i>Seminars in Oncology</i> , 2016, 43, 154-160.	2.2	27
20	The Androgen Receptor: Is It a Promising Target?. <i>Annals of Surgical Oncology</i> , 2017, 24, 2876-2880.	1.5	22
21	Mammographic screening in male patients at high risk for breast cancer: is it worth it?. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 705-711.	2.5	18
22	Spectrum of HIV lymphoma 2009. <i>Current Opinion in Hematology</i> , 2010, 17, 362-367.	2.5	17
23	A Randomized Multicenter Phase II Study of Docosahexaenoic Acid in Patients with a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease. <i>Cancer Prevention Research</i> , 2018, 11, 203-214.	1.5	17
24	Androgen receptorâ€positive, tripleâ€negative breast cancer. <i>Cancer</i> , 2017, 123, 1686-1688.	4.1	14
25	Androgen receptor splice variant-7 in breast cancer: clinical and pathologic correlations. <i>Modern Pathology</i> , 2022, 35, 396-402.	5.5	9
26	The microbial flora of taxane therapyâ€associated nail disease in cancer patients. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 607-609.	1.2	5
27	A multicenter phase II study of docosahexaenoic acid (DHA) in patients (pts) with a history of breast cancer (BC), premalignant lesions, or benign breast disease.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS1615-TPS1615.	1.6	2
28	The Androgen Receptor in Breast Cancer: Biology and Treatment Considerations. <i>Current Breast Cancer Reports</i> , 2012, 4, 56-65.	1.0	0